Treatment of Osteoporosis
Osteoporosis is a condition where bones become porous and fragile, greatly increasing fracture risk. It is often called a 'silent disease' because bone loss occurs without symptoms until a fracture happens, most commonly in the hip, spine, or wrist.
Managing Osteoporosis effectively requires a combination of medical treatment, lifestyle modification, and regular monitoring. With a structured management plan, most people with Osteoporosis can maintain a good quality of life and prevent serious complications.
First-Line Treatment Principles
- ✓Treat-to-target (T2T) strategy in RA and SpA: aim for remission or low disease activity
- ✓Disease-modifying antirheumatic drugs (DMARDs) initiated early in RA — methotrexate first-line
- ✓Biologic DMARDs (anti-TNF, anti-IL-6, JAK inhibitors) when csDMARD inadequate
- ✓Hydroxychloroquine and low-dose prednisolone for SLE; immunosuppressives for organ-threatening disease
- ✓Analgesia stepped approach: paracetamol → NSAIDs → opioids (short-term); topical agents in OA
What to Do Now
- Learn your personal risk factors for Osteoporosis (family history, age, lifestyle)
- Attend regular health check-ups and screening tests appropriate for your age and risk
- Track new or changing symptoms, especially those associated with Osteoporosis
- Use our AI symptom checker to assess whether your symptoms fit an early Osteoporosis pattern
- Discuss preventive strategies and early monitoring with your GP
- Build a personalised management plan with your GP or specialist
- Adhere consistently to prescribed medications — do not stop without medical advice
- Adopt a Osteoporosis-appropriate diet (anti-inflammatory, low-glycaemic, or disease-specific)
Medications Used in Osteoporosis
Alendronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption, used to treat and prevent osteoporosis and other metabolic bone diseases.
Risedronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption, used to treat and prevent osteoporosis and other metabolic bone diseases.
Ibandronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption, used to treat and prevent osteoporosis and other metabolic bone diseases.
Zoledronic Acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption, used to treat and prevent osteoporosis and other metabolic bone diseases.
Raloxifene is a selective estrogen receptor modulator (SERM) used to prevent and treat osteoporosis in postmenopausal women.
Denosumab is a RANK ligand inhibitor that prevents bone loss and is used to treat osteoporosis and bone metastases.
Teriparatide is used to treat severe osteoporosis by stimulating new bone formation through parathyroid hormone pathways.
Strontium Ranelate is used to treat severe osteoporosis by stimulating new bone formation through parathyroid hormone pathways.
Non-Pharmacological Management
- •Physical therapy: joint protection, range-of-motion exercises, strengthening — essential in OA and RA
- •Weight management: reduces mechanical load on hips/knees; reduces systemic inflammation
- •Occupational therapy: joint protection aids, assistive devices, workplace adaptations
- •Hydrotherapy and aquatic exercise: low-impact joint rehabilitation in OA
- •Dietary: Mediterranean diet reduces RA disease activity; omega-3 supplementation may reduce inflammation
- •Smoking cessation: major independent risk factor for RA initiation and worse disease course
- •Sun protection in SLE (UV can trigger flares)
Treatment Goals
Monitoring Parameters
- ◆Disease activity scores: DAS28 (RA), BASDAI/ASDAS (SpA), SLEDAI (lupus) — at 1, 3, 6 months
- ◆Shared care monitoring for methotrexate: FBC, LFTs monthly × 6, then every 3 months
- ◆Anti-TNF monitoring: TB screening (IGRA) before initiation; LTBI prophylaxis if positive
- ◆Bone mineral density: DEXA scan at baseline and every 2 years on long-term corticosteroids
- ◆Anti-dsDNA and complement (C3/C4) in SLE flare surveillance
- ◆Opthalmology: hydroxychloroquine retinopathy screening annually after 5 years use
Red Flags — When to Escalate
- ⚠Any of the characteristic symptoms of Osteoporosis — even mild — in a high-risk individual
- ⚠Progressive worsening of early warning signs over weeks
- ⚠Laboratory abnormalities (e.g., blood sugar, inflammatory markers) without full symptoms
- ⚠Unexplained weight loss, night sweats, or fatigue persisting >2 weeks
- ⚠Strong family history of Osteoporosis combined with new relevant symptoms
- ⚠Sudden worsening of Osteoporosis symptoms despite established treatment
Escalation Criteria
- →Inadequate response to methotrexate at 3 months → add hydroxychloroquine/sulfasalazine or switch to biologic
- →Lupus nephritis → high-dose prednisolone + mycophenolate or cyclophosphamide
- →Vasculitis with organ involvement → IV methylprednisolone + cyclophosphamide or rituximab
- →Septic arthritis: urgent joint aspiration + IV antibiotics; surgical washout if joint destruction
Special Populations
Clinical Insights
Compare With Similar Conditions
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →